Serotonin syndrome: Is it a reason to avoid the use of tramadol with antidepressants?

Journal of Pharmacy Practice

Volumn 27, Issue 1, 2014, Pages 71-78

  Park, Susie H ^a   Wackernah, Robin C ^b   Stimmel, Glen L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b REGIS UNIVERSITY   (United States)

Author keywords

antidepressants; drug drug interactions; serotonergic; serotonin syndrome; tramadol

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CYPROHEPTADINE; DESVENLAFAXINE; DEXTROMETHORPHAN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LINEZOLID; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PETHIDINE; RIZATRIPTAN; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; TRAMADOL; TRAZODONE; VENLAFAXINE; VILAZODONE; ZOLMITRIPTAN;

AGED; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; DRUG ANTAGONISM; DRUG METABOLISM; DRUG POTENTIATION; HUMAN; MONOTHERAPY; PHARMACOGENETICS; PHARMACOGENOMICS; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SEROTONIN SYNDROME;

ANTIDEPRESSANTS; DRUG-DRUG INTERACTIONS; SEROTONERGIC; SEROTONIN SYNDROME; TRAMADOL;

AGE FACTORS; ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; MONOAMINE OXIDASE INHIBITORS; RISK FACTORS; SEROTONIN SYNDROME; TRAMADOL;

EID: 84892768092     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190013504957     Document Type: Review

References (74)

1. Gillman PK. Serotonin-syndrome: history and risk. Fundam Clin Pharmacol. 1998 ; 12 (5). 482-491
2. Mills KC. Serotonin syndrome: a clinical update. Crit Care Clin. 1997 ; 13 (4). 763-783
3. Rosebush PI, Margetts P, Mazurek MF. Serotonin syndrome as a result of clomipramine monotherapy. J Clin Psychopharmacol. 1999 ; 19 (3). 285-287
4. Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999 ; 49 (448). 871-874
5. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004 ; 42 (3). 277-285
6. Sporer KA.. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf. 1995 ; 13 (2). 94-104
7. Lucki I, Nobler MS, Frazer A. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther. 1984 ; 228 (1). 133-139
8. Looper KJ. Potential medical and surgical complications of serotonergic antidepressant medications. Psychosomatics. 2007 ; 48 (1). 1-9
9. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 ; 352 (11). 1112-1120
10. Lappin RI, Auchincloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med. 1994 ; 331 (15). 1021-1022
11. Keck PE, Arnold LM. The serotonin syndrome. Psychiatr Ann. 2000 ; 30: 333-343
12. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome: presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000 ; 79 (4). 201-209
13. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991 ; 148 (6). 705-713
14. Dunkley EC, Isbister GK, Sibbritt D, et al. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003 ; 96 (9). 635-642
15. Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008 ; 7 (5). 587-596
16. Mitchell RS. Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Intern Med. 1955 ; 42 (2). 417-424
17. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003 ; 163 (20). 2433-2445
18. Mason BJ, Blackburn KH. Possible serotonin syndrome associated with tramadol and sertraline coadministration. Ann Pharmacother. 1997 ; 31 (2). 175-177
19. Shapira NA, Verduin ML, DeGraw JD. Treatment of refractory major depression with tramadol monotherapy (letter). J Clin Psychiatry. 2001 ; 62 (3). 205-206
20. Shapira NA, Keck PE, Goldsmith TD, et al. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety. 1997 ; 6 (4). 170-173
21. Goldsmith TD, Shapira NA, Keck PE. Rapid remission of OCD with tramadol hydrochloride. Am J Psychiatry. 1999 ; 156 (4). 660-661
22. Shapira NA, McConville BJ, Pagnucco ML, et al. Novel use of tramadol hydrochloride in the treatment of Tourette's Syndrome. J Clin Psychiatry. 1997 ; 58 (4). 174-175
23. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther. 1992 ; 260 (1). 275-285
24. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004 ; 43 (13). 879-923
25. Cicero TJ, Adams EH, Geller A, et al. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend. 1999 ; 57 (1). 7-22
26. Paar WD, Frankus P, Dengler HJ. The metabolism of tramadol by human liver microsomes. Clin Investig. 1992 ; 70 (80). 708-710
27. Paar WD, Poche S, Gerloff J, Dengler HJ. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol. 1997 ; 53 (3-4). 235-239
28. Poulsen L, Arendt-Nielsen L, Brøsen K, Sundrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther. 1996 ; 60 (6). 636-644
29. Reimann W, Schneider F. Induction of 5-hydroxytryptamine release by tramadol, fenfluramine, and reserpine. Eur J Pharmacol. 1998 ; 349 (2-3). 199-203
30. Gobbi M, Mennini T. Release studies with rat brain cortical synaptosomes indicate that tramadol is a 5-hydroxytryptamine uptake blockers and not a 5-hydroxytryptomine releaser. Eur J Pharmacol. 1999 ; 370 (1). 23-26
31. Takeshita J, Litzinger MH. Serotonin syndrome associated with tramadol. Prim Care Companion J Clin Psychiatry. 2009 ; 11 (5). 273
32. Tashakori A, Afshari R. Tramadol overdose as a cause of serotonin syndrome: a case series. Clin Toxicol (Phila). 2010 ; 48 (4). 337-341
33. Peacock LE, Wright F. Serotonin syndrome secondary to tramadol and citalopram. Age Ageing. 2011 ; 40 (4). 528
34. Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine and mirtazapine. Ann Pharmacother. 2004 ; 38 (3). 411-413
35. Mahlberg R, Kunz D, Sasse J, Kirchheiner J. Serotonin syndrome with tramadol and citalopram. Am J Psychiatry. 2004 ; 161 (6). 1129
36. Mittino D, Mula M, Monaco F. Serotonin syndrome associated with tramadol-sertraline coadministration. Clin Neuropharmacol. 2004 ; 27 (3). 150-151
37. Gonzalez-Pinto A, Imaz H, De Heredia JL, et al. Mania and tramadol-fluoxetine combination. Am J Psychiatry. 2001 ; 158 (6). 964-965
38. Kesavan S, Sobala GM. Serotonin syndrome with fluoxetine plus tramadol. J R Soc Med. 1999 ; 92 (9). 474-475
39. Lantz MS, Buchalter EN, Giambanco V. Serotonin syndrome following the administration of tramadol with paroxetine. Int J Geriatr Psychiatry. 1998 ; 13 (5). 343-345
40. Egberts AC, ter Borgh J, Brodie-Meijer CC. Serotonin syndrome attributed to tramadol addition to paroxetine therapy. Int Clin Psychopharmacol. 1997 ; 12 (3). 181-182
41. Dimellis D. Serotonin syndrome produced by a combination of venlafaxine and mirtazapine. World J Biol Psychiatry. 2002 ; 3 (3). 167
42. Markowitz JS, Patrick KS. Venlafaxine-tramadol similarities. Med Hypotheses. 1998 ; 51 (2). 167-168
43. Raritan, NJ: Ultram (tramadol) ; 2009 :
44. Laugesen S, Enggaard TP, Pedersen RS, et al. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther. 2005 ; 77 (4). 312-323
45. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997 ; 60 (2). 284-295
46. Evans DA, Mahgoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 ; 17 (2). 102-105
47. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol. 1990 ; 39 (6). 533-537
48. van der Weide J, Hinrichs JW. The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. Clin Biochem Rev. 2006 ; 27 (1). 17-25
49. Pan JJ, Shen WW. Serotonin syndrome induced by low-dose venlafaxine. Ann Pharmacother. 2003 ; 37 (2). 209-211
50. Muzyk AJ, Jakel RJ, Preud'homme X. Serotonin syndrome after a massive overdose of controlled-release paroxetine. Psychosomatics. 2010 ; 51 (5). 437-442
51. Kolecki P. Isolated venlafaxine-induced serotonin syndrome. J Emerg Med. 1997 ; 15 (4). 491-493
52. Gelener P, Gorgulu U, Kutlu G, et al. Serotonin syndrome due to duloxetine. Clin Neuropharmacol. 2001 ; 34 (3). 127-128
53. Fischer P. Serotonin syndrome in the elderly after antidepressive monotherapy. J Clin Psychopharmacol. 1995 ; 15 (6). 440-442
54. Hernández JL, Ramos FJ, Infante J, et al. Severe serotonin syndrome induced by mirtazapine monotherapy. Ann Pharmacother. 2002 ; 36 (4). 641-643
55. Ubogu EE, Katirji B. Mirtazapine-induced serotonin syndrome. Clin Neuropharmacol. 2003 ; 26 (2). 54-57
56. Yacoub HA, Johnson WG, Souayah N. Serotonin syndrome after administration of milnacipran for fibromyalgia. Neurology. 2010 ; 74 (8). 699-700
57. Pearce S, Ahned N, Varas GM. A case study of delayed serotonin syndrome: lessons learned. Consult Pharm. 2009 ; 24 (1). 64-68
58. Shatin D, Gardner JS, Stergachis A, et al. Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants. Pharmacoepidemiol Drug Saf. 2005 ; 14 (3). 149-154
59. St. Louis, MO: Celexa (citalopram) ; 2011 :
60. Research Triangle Park, NC: Paxil (paroxetine) ; 2011 :
61. Philadelphia, PA: Effexor XR (venlafaxine) ; 2009 :
62. Indianapolis, IN: Cymbalta (duloxetine) ; 2011 :
63. Kenilworth, NJ: Remeron (mirtazapine) ; 2010 :
64. New Haven, CT: Viibryd (vilazodone) ; 2011 :
65. Peck AW, Stern WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry. 1983 ; 44 (5 pt 2). 197-210
66. Labate A, Newton MR, Vernon GM, et al. Tramadol and new-onset seizures. Med J Aust. 2005 ; 182 (1). 42-43
67. Marquardt KA, Alsop JA, Albertson TE. Tramadol exposures reported to statewide poison control system. Ann Pharmacother. 2005 ; 39 (6). 1039-1044
68. Spiller HA, Gorman SE, Villalobos D, et al. Prospective multicenter evaluation of tramadol exposure. J Toxicol Clin Toxicol. 1997 ; 35 (4). 361-364
69. Talaie H, Panahandeh R, Fayaznouri M, et al. Dose-independent occurrence of seizure with tramadol. J Med Toxicol. 2009 ; 5 (2). 63-67
70. Gasse C, Derby L, Vasilakis-Scaramozza C, et al. Incidence of first-time idiopathic seizures in users of tramadol. Pharmacotherapy. 2000 ; 20 (6). 629-634
71. Gardner JS, Blough D, Drinkard CR, et al. Tramadol and seizures: a surveillance study in a managed care population. Pharmacotherapy. 2000 ; 20 (12). 1423-1431
72. Boyd IW. Tramadol and seizures (letter). Med J Aust. 2005 ; 182 (11). 595-596
73. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry. 1989 ; 50 (7). 256-261
74. Skowron DM, Stimmel GL. Antidepressants and the risk of seizures. Pharmacotherapy. 1992 ; 12 (1). 18-22